Search

132 Result(s)
Sort by

NeO - smart and sustainable vaccines

NeO - smart and sustainable vaccines

The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Empowering all employees

Empowering all employees

Boehringer Ingelheim has been awarded as a Global Top Employer for the second year in succession
China pioneers biosecurity report against ASF

China pioneers biosecurity report against ASF

Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Beyond the Stigma

Beyond the Stigma

Hear first-hand a patient and caregiver’s perspective of living with schizophrenia.
Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Obesity osteoarthritis in pets a blind spot

Obesity osteoarthritis in pets a blind spot

Same as with humans, body weight is just one indicator among many when it comes to a pet’s health status. However, there are some diseases associated with it. Learn more here.
Spotlight on GPP

Spotlight on GPP

Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.